Skip to main content
Equibles
HIMS logo

HIMS · Hims & Hers Health, Inc. · Metrics

Track HIMS — free

Use HIMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HIMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.35 +1.20 (+4.26%)
S&P 400 member Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 10% of receivables

One customer — 10% of receivables (December 31, 2025)

“As of December 31, 2025, one customer or partner individually represented more than 10% of accounts receivable.”

4 customers — 10% of receivables (December 31, 2024)

“As of December 31, 2024, four customers or partners individually represented more than 10% of accounts receivable.”
View the 10-K filed Feb 23, 2026
Market Cap
$6.57B
Shares
233.31M
Volume · Oct 20 10.53M Avg daily vol (3M) 12.08M

HIMS metrics

83 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$29.21
Market cap
$6.57B

Price action

20 metrics
Price change (1W)
-8.1%
Price change (30D)
-4.1%
Price change (3M)
-13.9%
Price change (6M)
-9.2%
Price change (YTD)
-13.3%
Price change (1Y)
-43.5%
Trailing year
Price change (5Y)
+240.8%
52-week high
$51.36
52-week low
$14.52
Change from 52-week high
-45.2%
Change from 52-week low
+93.9%
Annualized volatility
89.1%
Annualized volatility (3M)
83.6%
Beta
2.9
RSI (14D)
46.1
Price vs SMA 50
-3.8%
Price vs SMA 200
+3.3%
Avg volume (3M)
12.05M
Relative volume
0.6
Average dollar volume
$356.17M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
233.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 39.4%
P / book
20.2
reciprocal yield 4.9%
FCF yield
0.9%
TTM · current market cap
Buyback yield
1.4%
P / FCF
106.2
reciprocal yield 0.9%
P / operating cash flow
24.9
reciprocal yield 4.0%
Earnings yield
-2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
89.0×
reciprocal yield 1.1%
P / E historical average (5Y)
89.0×
reciprocal yield 1.1%
EV / revenue historical average (3Y)
3.8×
reciprocal yield 26.7%
EV / revenue historical average (5Y)
3.6×
reciprocal yield 27.5%
EV / EBIT historical average (3Y)
158.1×
reciprocal yield 0.6%
EV / EBIT historical average (5Y)
158.1×
reciprocal yield 0.6%
EV / EBITDA historical average (3Y)
306.2×
reciprocal yield 0.3%
EV / EBITDA historical average (5Y)
306.2×
reciprocal yield 0.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-09
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
68.4%
Operating margin
-6.0%
Trailing 12 months
Net margin
-5.5%
Gross profit (TTM)
$1.76B
Operating profit (TTM)
−$154.52M
Net income (TTM)
−$142.03M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
2.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+38.2%
Year over year
Net income growth YoY
-303.0%
Revenue (TTM)
$2.58B
Trailing 12 months
EPS growth YoY
-317.6%
Shares change YoY
-9.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+64.5%
Revenue CAGR (5Y)
+73.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-43.8%
Return on assets
-3.9%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
−$67.33M
Free cash flow (TTM)
$61.65M
Quick ratio
0.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$609.81M
Total assets
$3.63B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$263.45M
Capital expenditures (TTM)
$201.80M
R&D (TTM)
—
SG&A (TTM)
$175.65M
Stock compensation (TTM)
$153.64M
R&D / revenue
—
Stock compensation / revenue
6.0%

Ownership (13F)

9 metrics
13F filers
522
13F filer change QoQ
+78
Institutional ownership
94.5%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.7%
Holder tenure
11.6
Price vs estimated holder cost
+33.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
21.5%

Short interest

3 metrics
Short interest
23.5%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.86M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1773751 CUSIP 433000106 13F (30d) 54 filings 47 filers Visit website Investor relations